Chief Scientist: R&D budget needs extra NIS 1b

"Budgeting inconsistency sends a signal of instability to investors, and even in times of budget difficulties, it’s illogical to harm the most effective means for guaranteeing growth and jobs."

“The R&D budget lacks NIS 1 billion a year,” says Chief Scientist Dr. Eli Opper. He says the NIS 200 million cut in the Chief Scientist’s budget is harming Israel’s R&D inventory. “Budgeting inconsistency sends a signal of instability to investors, and even in times of budget difficulties, it’s illogical to harm the most effective means for guaranteeing growth and jobs,”

Since January 2006, the Office of the Chief Scientist has received applications for supporting R&D totaling over NIS 5 billion altogether. In 2005, the Chief Scientist and Ministry of Finance agreed on a three-year NIS 600 million budget supplement for the office.

On the basis of this agreement, the Office of the Chief Scientist declared nanotechnology, biotechnology and low technology as preferred sectors for increased budgets. The Chief Scientist also launched a program for encouraging R&D and adopting new technologies in low technology industries, on the assumption that knowledge intensive factories will improve their global position through higher competitiveness. The Chief Scientist also decided to establish a biotechnology fund amounting to hundreds of millions of dollars. The office says any cut in its budget will jeopardize these plans.

The Office of the Chief Scientist asserts that leading economists believe that R&D performance accounts for a substantial part of economic growth. R&D is estimated to contribute 45% to the rise in productivity in the Israeli economy, and it contributes an estimated 30% to Israel’s annual return on R&D investment.

Published by Globes [online], Israel business news - www.globes.co.il - on September 12, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters